See more : OPT-Sciences Corporation (OPST) Income Statement Analysis – Financial Results
Complete financial analysis of Satellos Bioscience Inc. (MSCL.TO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Satellos Bioscience Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Fortune Bay Corp. (FTBYF) Income Statement Analysis – Financial Results
- Indo Count Industries Limited (ICIL.NS) Income Statement Analysis – Financial Results
- Schweiter Technologies AG (SCWTF) Income Statement Analysis – Financial Results
- FinTech Global Incorporated (8789.T) Income Statement Analysis – Financial Results
- American Electric Power Company, Inc. (AEP) Income Statement Analysis – Financial Results
Satellos Bioscience Inc. (MSCL.TO)
About Satellos Bioscience Inc.
Satellos Bioscience Inc., a biotechnology company, develops regenerative therapeutics to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system which recapitulates the muscle stem cell environment ex-vivo. Its lead program focuses on the discovery and development of a small molecule drug for the treatment of Duchenne. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 25.00K |
| Cost of Revenue | 8.82M | 3.73M | 119.92K | 48.16K | 1.28M |
| Gross Profit | -8.82M | -3.73M | -119.92K | -48.16K | -1.26M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -5,030.14% |
| Research & Development | 8.82M | 3.73M | 2.00M | 892.78K | 1.28M |
| General & Administrative | 6.06M | 3.96M | 1.44M | 182.36K | 835.81K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 35.04K |
| SG&A | 6.06M | 3.96M | 1.44M | 182.36K | 1.23M |
| Other Expenses | 0.00 | -48.67K | -43.84K | -75.01K | 0.00 |
| Operating Expenses | 15.46M | 8.43M | 4.70M | 1.43M | 743.80K |
| Cost & Expenses | 15.46M | 8.43M | 4.70M | 1.48M | 2.03M |
| Interest Income | 1.33M | 63.00K | 7.99K | 4.97K | 12.88K |
| Interest Expense | 177.00K | 0.00 | 985.33K | 23.05K | 0.00 |
| Depreciation & Amortization | 7.00K | 337.00K | 165.69K | 422.00 | 734.00 |
| EBITDA | -15.71M | -8.09M | -4.60M | -1.61M | -2.00M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -7,995.23% |
| Operating Income | -15.46M | -8.43M | -4.74M | -1.55M | -2.00M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -7,998.16% |
| Total Other Income/Expenses | -426.00K | -2.89M | -8.86M | 349.79K | 217.22K |
| Income Before Tax | -15.89M | -11.32M | -15.51M | -1.58M | -1.99M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -7,953.81% |
| Income Tax Expense | 0.00 | 5.00K | 941.49K | -51.96K | 0.00 |
| Net Income | -15.89M | -11.32M | -15.51M | -1.58M | -1.99M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -7,953.81% |
| EPS | -0.18 | -0.32 | -0.64 | -0.05 | -0.18 |
| EPS Diluted | -0.18 | -0.32 | -0.64 | -0.05 | -0.18 |
| Weighted Avg Shares Out | 86.40M | 35.68M | 24.08M | 32.87M | 10.91M |
| Weighted Avg Shares Out (Dil) | 86.40M | 35.68M | 24.08M | 32.87M | 10.91M |
Source: https://incomestatements.info
Category: Stock Reports